Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation

David Hickey, John Cant, Mark S. Soloway

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Using historical controls, we analyzed the effect of chemotherapy on survival of patients with metastatic prostate cancer who failed androgen deprivation. The survival of 178 patients with metastatic prostate cancer who receive palliation only after failing hormonal therapy was compared with the survival of 27 patients who received chemotherapy on NPCP Protocol 1500. Survival was measured from the initiation of androgen deprivation. The mean survival after chemotherapy was 8.4 months which was slightly less than the group receiving palliation only. At this time, chemotherapy has not been able to improve survival in patients with metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)38-40
Number of pages3
JournalUrology
Volume31
Issue number1
DOIs
StatePublished - Jan 1988

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation'. Together they form a unique fingerprint.

Cite this